B
inding of FccRs, integral surface membrane glycoproteins, with the Fc portion of IgG is a crucial mechanism for transmitting the stimulative or repressive immune responses. FccR binding may initiate a plethora of biological responses, including phagocytosis, the facilitation of antigen presentation, and the processing of immune complexes. 1 Patients with systemic lupus erythematosus (SLE) exhibit the profound defect of phagocytosis in immune complex processing. 2 Human SLE pedigree studies with genome-wide scans have mapped chromosome 1q21-24, in which the FccR gene cluster is found as an important locus. 3 4 The genetic heterogeneity of FccR may have an impact on numerous autoimmune diseases and infections, especially lupus nephritis. 5 Subsequent FccR genetic association analysis of lupus disclosed controversial or discrepant results across various study groups, suggesting that ethnic and geographical factors may cause various disease susceptibilities and complexities of lupus.
FccRIIa H/R131 polymorphism showed a significantly skewed distribution in several non-Caucasian lupus studies, which might also influence the disease manifestations in Caucasian lupus patients. 6 7 Recently, studies of Japanese and Korean lupus patients showed that FccRIIa H/R131 polymorphism was an important genetic factor. 8 9 FccRIIIa F/ V158 polymorphism has been shown to be an important susceptibility gene in Caucasian lupus studies. 10 FccRIIIb NA1/NA2 was also linked to lupus susceptibility in one Japanese population study and, in particular, in Caucasian patients with lupus nephritis. 11 12 In view of these positional and functional candidate gene approaches, the effects of genotype variants of three FccRs in Taiwan lupus patients were investigated.
PATIENTS AND METHODS
Characteristics of study groups A total of 302 patients with SLE in Taiwan were studied. For this study, 311 healthy blood donors were selected as controls after a questionnaire survey to exclude autoimmune diseases. Patients enrolled in this study were prospectively followed up in the rheumatology clinics of Chang Gung Memorial Hospital. All the patients were evaluated by rheumatology specialists to verify that they fulfilled the 1982 and 1997 American College of Rheumatology criteria for SLE. Clinical manifestations of lupus and related serological findings were based on the American College of Rheumatology definition in the classification criteria. Patients were grouped as positive or negative according to presentation within the first year of lupus diagnosis. Associated infections during the course of the disease were all recorded, and were supported by positive culture.
Nucleic acid extraction and allele-specific polymerase chain reaction for FccR genotyping Genomic DNA was extracted from EDTA-anticoagulated peripheral blood using the DNA isolation kit. Each of the three primers was designed for allele-specific polymerase chain reaction for the genotyping of FccRIIa H/R131, FccRIIIa F/V158 and FccRIIIb NA1/NA2 as previously described. 13 
Statistical analysis
The frequencies of the genotypes of the three FccR polymorphisms in patients and controls were compared using a paired t test and a x 2 test. Data were analysed with the SPSS statistic package for Windows, and Fisher's exact test applied. Distribution of the variant genotypes was also compared between lupus patients with and without different clinical manifestations and autoantibodies. A p value ,0.05 was considered significant.
RESULTS

Clinical characteristics of SLE
This study enrolled 302 patients (91% women) with SLE from Taiwan with a mean age of lupus onset of 29.3 (11.5) years (range 11-77). Haematological disorders (233/302 (77.2%)) were the most common manifestation, followed by malar rash (206/302 (68.2%)) and arthritis (194/302 (64.2%)). One hundred and fifty five (51.3%) patients developed nephritis, 70 (23.2%) patients had nephrotic syndrome (proteinuria >3.5 gm/day), and 17 (5.6%) patients progressed to end stage renal disease. The incidence of other manifestations was as follows: 32.5% oral ulcer, 26.5% serositis, 25.8% vasculitis, 24.8% photosensitivity, 21.9% discoid rash, 13.9% Raynaud's phenomenon, and 11.9% neuropsychiatric manifestations. The age onset of lupus was most frequent from 20 to 29 years old (123 patients). In comparison with patients with age onset .20 years old, the patients with an earlier onset (age,20 years) had a higher frequency of FccRIIa H/ H131 (p = 0.01) ( *p = 0.01 (patients with age at onset ,20 years compared with age at onset >20 years).Àp = 0.055;`p = 0.051; 1 = 0.095; ôp = 0.039; **p = 0.005; ÀÀp = 0.028. and FcRIIIb NA1/NA2 for anti-Smith, anti-RNP, anti-dsDNA, anticardiolipin, and hypocomplementaemia in the examined patients were seen.
FcR genotyping and infections
One hundred and twenty five lupus patients had 174 episodes of infection. Sixteen patients developed infections at lupus onset. Urinary tract infections (57 episodes) and herpes viral infections (37 episodes) were the most common infections in this study. Other infections were as follows: 26 cases of sepsis, 15 cases of skin wound infection, 9 cases of pneumonia, 3 cases of emphysema, 2 cases of biliary tract infections, 5 cases each of septic arthritis and meningitis. Nine episodes of fungus and five of tuberculosis infections were noted. The organisms most commonly found were 16 E coli infections of urinary tract infections, 10 Salmonella infections of sepsis, and 4 Cryptococcus infections of meningitis. The FcRIIIa V/V158 genotype was more frequently found in lupus patients who had with infections than those without (19.2% v 11.9%, p = 0.039).
DISCUSSION
FcR polymorphisms are the most important non-major histocompatibility complex lupus susceptibility loci. The inconsistencies among earlier lupus genetic association studies of FcR are attributable to many biases, including ethnic variation, population admixture, the production of various IgG subclass autoantibodies, distinct phenotypic expressions, and the confounding influence of other inherited factors. In a review of previous reports of FcR polymorphism, the significant association of disease susceptibility in lupus case-control studies was not noted in the following studies with larger populations. 11 14 Thus, 302 Taiwanese lupus patients were enrolled and compared with 311 sex matched healthy controls in this study.
A review of published reports showed that the FcRIIa R/ R131 genotype is susceptible to lupus, particularly lupus nephritis. However, Karassa et al in a meta-analysis study demonstrated that FcRIIa R/R131 had no clear effect on the development of nephritis in SLE. The Asian population has a lower frequency of FcRIIa R/R131 than populations of other ethnic origin. 6 Similar low frequencies of FcRIIa R/R131 genotypes, 16.2% and 11.9%, were found in our lupus group and healthy control group, respectively. Manger et al demonstrated associations of various clinical symptoms and immunological disorders with FcR IIa H/R131 polymorphism. 7 FccIIa H/H131 was found to protect against the development of lupus nephritis in this study.
FcRIIIa F/V158 genotype is a susceptible gene, according to several Caucasian and Japanese studies 10 13 14 but shows a distribution that is not significantly different between patients and controls in most Asian lupus studies. The distribution of the FccRIIIa F/V158 polymorphism was reported to be associated with various clinical manifestations. FccRIIIa V/V158 combined with FcRIIa H/H131 had a protective role for lupus nephritis in Korean and German studies. 7 8 In this study, we could not find such an effect. Dijstelbloem et al found that lupus patients who presented with arthritis and/or serositis had a high frequency of FcRIIIa F/F158. 12 Interestingly, we found a trend towards an association of FcRIIIa F/F158 with neuropsychiatric manifestations.
FcRIIIb NA2/NA2 polymorphism was related to lupus susceptibility and nephritis in a Japanese study. Subsequently, this association was claimed to involve perhaps another important FcRIIb polymorphism. 14 Dijstelbloem et al also showed that FcRIIIb NA1/NA1 was related to susceptibility to nephritis. 12 The FcRIIIb NA1/NA2 genotype did not show a significantly skewed distribution of lupus susceptibility in Taiwanese lupus patients. In this study, patients with FcRIIIb NA1/NA1 may have been protected against central nervous system involvement. Unexpectedly, FcRIIa H/H131 and FcRIIIb NA1/NA1 showed a high frequency in discoid rash.
FcRIIIb NA1/NA2 and FcRIIa H/R131 have been shown to contribute to encapsulated bacterial infections with various neutrophil phagocytosis activities. 15 In our study, there were few encapsulated bacteria infections, and FcRIIIb NA1/NA2 and FcRIIa H/R131 polymorphisms had no significant role in patients with other associated infections. Interestingly, our lupus patients with infections had a higher frequency of the FcRIIIa V/V158 genotype. The result may be due to the high incidence of herpes virus and opportunistic infections in our lupus patients.
In conclusion, FcR IIa, IIIa, and IIIb polymorphisms may contribute to clinical manifestations of lupus and related infections but do not indicate a significant susceptibility to lupus in Taiwanese patients.
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